Simvastatin abates development of renal fibrosis in experimental renovascular disease

Journal of Hypertension

Volumn 26, Issue 8, 2008, Pages 1651-1660

  Chade, Alejandro R ^a,d   Zhu, Xiang Yang ^a   Grande, Joseph P ^b   Krier, James D ^a   Lerman, Amir ^c   Lerman, Lilach O ^a,c  

^a Divisions of Nephrology and Hypertension ^*  (United States)

^b Laboratory Medicine and Pathology   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Epithelial to mesenchymal transition; Kidney; Remodeling; Simvastatin

Indexed keywords

OSTEOGENIC PROTEIN 1; SCATTER FACTOR; SIMVASTATIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME REGULATION; GLOMERULOSCLEROSIS; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; KIDNEY ARTERY STENOSIS; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENOVASCULAR DISEASE; SIGNAL TRANSDUCTION; SWINE; ANIMAL; ATHEROSCLEROSIS; DISEASE MODEL; DRUG EFFECT; EPITHELIUM CELL; FIBROSIS; GLOMERULUS FILTRATION RATE; KIDNEY CIRCULATION; MESENCHYMAL STEM CELL; PATHOLOGY; RENOVASCULAR HYPERTENSION;

ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FIBROSIS; GLOMERULAR FILTRATION RATE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, RENAL; MESENCHYMAL STEM CELLS; RENAL ARTERY OBSTRUCTION; RENAL CIRCULATION; SIMVASTATIN; SUS SCROFA;

EID: 51549098456     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328302833a     Document Type: Article

References (58)

1. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation 2005; 112:1362-1374.
2. van Ampting JM, Penne EL, Beek FJ, Koomans HA, Boer WH, Beutler JJ. Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003; 18:1147-1151.
3. Chade AR, Rodriguez-Porcel M, Grande JP, Krier JD, Lerman A, Romero JC, et al. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation 2002; 106:1165-1171.
4. Chade AR, Rodriguez-Porcel M, Grande JP, Zhu X, Sica V, Napoli C, et al. Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23:1295-1301.
5. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, et al. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 2004; 15:958-966.
6. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15:290-301.
7. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004; 82:175-181.
8. Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003; 12:25-29.
9. Wright JR, Duggal A, Thomas R, Reeve R, Roberts IS, Kalra PA. Clinicopathological correlation in biopsy-proven atherosclerotic nephropathy: implications for renal functional outcome in atherosclerotic renovascular disease. Nephrol Dial Transplant 2001; 16:765-770.
10. Lerman LO, Chade AR. Atherosclerotic process, renovascular disease and outcomes from bench to bedside. Curr Opin Nephrol Hypertens 2006;15:583-587.
11. Auer J, Berent R, Weber T, Eber B. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr Med Chem 2002; 9:1831-1850.
12. Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol 2005; 16(Suppl 1):S11-S17.
13. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J 2006; 20:1706-1708.
14. Lerman LO, Schwartz RS, Grande JP, Sheedy PF, Romero JC. Noninvasive evaluation of a novel swine model of renal artery stenosis. J Am Soc Nephrol 1999; 10:1455-1465.
15. Wilson HM, Reid FJ, MacLeod AM, Haites NE, Booth NA. Transforming growth factor beta (TGF-beta) regulates the matrix-associated plasminogen activator inhibitor 1. (PAI-1) in glomerular mesangial and epithelial cells. Exp Nephrol 1995; 3:141-142.
16. Chade AR, Rodriguez-Porcel M, Herrmann J, Krier JD, Zhu X, Lerman A, Lerman LO. Beneficial effects of antioxidant vitamins on the stenotic kidney. Hypertension 2003; 42:605-612.
17. Krier JD, Ritman EL, Bajzer Z, Romero JC, Lerman A, Lerman LO. Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function. Am J Physiol Renal Physiol 2001; 281:F630-F638.
18. Lerman LO, Bell MR, Lahera V, Rumberger JA, Sheedy PF, Sanchez Fueyo A, Romero JC. Quantification of global and regional renal blood flow with electron beam computed tomography. Am J Hypertens 1994; 7:829-837.
19. Chade AR, Bentley MD, Zhu X, Rodriguez-Porcel M, Niemeyer S, Amores- Arriaga B, et al. Antioxidant intervention prevents renal neovascularization in hypercholesterolemic pigs. J Am Soc Nephrol 2004; 15:1816-1825.
20. Chade AR, Herrmann J, Zhu X, Krier JD, Lerman A, Lerman LO. Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. J Am Soc Nephrol 2005; 16:1005-1012.
21. Chade AR, Krier JD, Rodriguez-Porcel M, Breen JF, McKusick MA, Lerman A, Lerman LO. Comparison ofacute and chronic antioxidant interventions in experimental renovascular disease. Am J Physiol Renal Physiol 2004;286:F1079-F1086.
22. Chade AR, Mushin OP, Zhu X, Rodriguez-Porcel M, Grande JP, Textor SC, et al. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension 2005; 46:772-779.
23. Mui KW, Sleeswijk M, van den Hout H, van Baal J, Navis G, Woittiez AJ. Incidental renal artery stenosis is an independent predictor of mortality in patients with peripheral vascular disease. J Am Soc Nephrol 2006; 17:2069-2074.
24. Balk E, Raman G, Chung M, Ip S, Tatsioni A, Alonso A, et al. Effectiveness of management strategies for renal artery stenosis: a systematic review. Ann Intern Med 2006; 145:901-912.
25. Tumelero RT, Duda NT, Tognon AP, Thiesen M. Prevalence of renal artery stenosis in 1656. patients who have undergone cardiac catheterization. Arq Bras Cardiol 2006; 87:248-253.
26. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172:973-981.
27. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, et al. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 2004; 65:871-880.
28. Ohtaka A, Ootaka T, Sato H, Ito S. Phenotypic change of glomerular podocytes in primary focal segmental glomerulosclerosis: developmental paradigm? Nephrol Dial Transplant 2002; 17. (Suppl 9):11-15.
29. Sam R, Wanna L, Gudehithlu KP, Garber SL, Dunea G, Arruda JA, Singh AK. Glomerular epithelial cells transform to myofibroblasts: early but not late removal of TGF-beta1. reverses transformation. Transl Res 2006; 148:142-148.
30. Gore-Hyer E, Shegogue D, Markiewicz M, Lo S, Hazen-Martin D, Greene EL, et al. TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physio! Renal Physio! 2002; 283:F707-F716.
31. Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transp!ant 2006; 6:2937-2946.
32. Vieira JM Jr, Mantovani E, Rodrigues LT, Delle H, Noronha IL, Fujihara CK, Zatz R. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephro! Dial Transp!ant 2005; 20:1582-1591.
33. Zhang G, Kernan KA, Collins SJ, Cai X, Lopez-Guisa JM, Degen JL, et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to- mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephro! 2007; 18:846-859.
34. Zhang C, Meng X, Zhu Z, Liu J, Deng A. Connective tissue growth factor regulates the key events in tubular epithelial to myofibroblast transition in vitro. Cell Bio! Int 2004; 28:863-873.
35. Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am J Physio! Lung Cell Mol Physio! 2004; 287:L1323-L1332.
36. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation ofSmad2. and Smad3. in TGF-beta signaling. J Cell Biochem 2007; 101:9-33.
37. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME. The differential role of Smad2. and Smad3. in the regulation of pro-fibrotic TGFbeta1. responses in human proximal-tubule epithelial cells. Biochem J 2006; 393. (Pt 2):601-607.
38. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth factor-beta1. mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Bio! Cell 2001; 12:27-36.
39. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R. BMP-7. counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9:964-968.
40. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Bio! 2006; 7:131-142.
41. Patel S, Mason RM, Suzuki J, Imaizumi A, Kamimura T, Zhang Z. Inhibitory effectofstatins on renal epithelial-to-mesenchymal transition. Am JNephro! 2006; 26:381-387.
42. Wolf G. Renal injury due to renin -angiotensin -aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006;70:1914-1919.
43. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circu!ation 2005; 111:2509-2517.
44. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425:577-584.
45. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Bio! Cell 2005; 16:1987-2002.
46. Gong R, Rifai A, Dworkin LD. Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium. J Am Soc Nephro! 2006; 17:2464-2473.
47. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physio! Renal Physio! 2004; 287:F7-F16.
48. Esposito C, Parrilla B, De Mauri A, Cornacchia F, Fasoli G, Foschi A, et al. Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli. Kidney Int 2005; 67:2143-2150.
49. Jarvisalo MJ, Juonala M, Raitakari OT. Assessment of inflammatory markers and endothelial function. Curr Opin C!in Nutr Metab Care 2006; 9:547-552.
50. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004; 35. (11. Suppl 1):2708-2711.
51. Takeya R, Sumimoto H. Regulation of novel superoxide-producing NAD(P)H oxidases. Antioxid Redox Signal 2006; 8:1523-1532.
52. Ren Y, Garvin JL, Falck JR, Renduchintala KV, Carretero OA. Glomerular autacoids stimulated by bradykinin regulate efferent arteriole tone. Kidney Int 2003; 63:987-993.
53. Ito S, Abe K. Contractile properties of afferent and efferent arterioles. C!in Exp Pharmaco! Physio! 1997; 24:532-535.
54. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, UretskyBF. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005; 65:345-355.
55. Inman SR, Davis NA, Mazzone ME, Olson KM, Lukaszek VA, Yoder KN. Simvastatin and L-arginine preserve renal function after ischemia/reperfusion injury. Am J Med Sci 2005; 329:13-17.
56. Carey GB. The swine as a model for studying exercise-induced changes in lipid metabolism. Med Sci Sports Exerc 1997; 29:1437-1443.
57. Hasler-Rapacz J, Kempen HJ, Princen HM, Kudchodkar BJ, Lacko A, Rapacz J. Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine. Arteriosc!er Thromb Bio! 1996; 16:137-143.
58. Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, Lee HB. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephro! 2005; 16:667-675.